Phase 2 N=19 Randomized Double-blind Supportive Care

High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients

Cancer

Bottom Line

View on ClinicalTrials.gov: NCT02932332 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2021

Primary outcome: Primary: Change in Dyspnea Numeric Score Between 0 and 10 Minutes — -1.8; -1.8; -0.6; -0.5 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: High-flow Oxygen (Other); Low-flow Oxygen (Other); High-flow Air (Other); Low-flow Air (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: M.D. Anderson Cancer Center
Primary completion: Mar 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Dyspnea Numeric Score Between 0 and 10 Minutes	-1.8; -1.8; -0.6; -0.5	—
SECONDARY Change in Modified Borg Scale Intensity Between 0 and 10 Minutes	-0.7; -1.8; -0.1; -0.5	—
SECONDARY Change in Modified Borg Scale Unpleasantness Between 0 and 10 Minutes	-0.5; -1.8; -0.6; -0.7	—

Summary

The goal of this clinical research study is to compare high-flow oxygen, low-flow oxygen, high-flow air, and low-flow air in helping to decrease shortness of breath in cancer patients. Researchers also want to learn if these therapies can help to improve lung function and quality of life.

Eligibility Criteria

Inclusion Criteria

Diagnosis of cancer
Patients seen by palliative care, thoracic oncology, pulmonary medicine, or emergency care at MD Anderson Cancer Center
Dyspnea Numeric Rating Scale at rest >/=3 of 10 (average over last 24 hour)
Non-hypoxemic (i.e. oxygen saturation >90% on ambient air)
Able to communicate in English or Spanish
Age >/= 18 years
Able to tolerate high-flow oxygen/air

Exclusion Criteria

Memorial Delirium Rating Scale >13
Hemodynamic instability
Respiratory failure requiring mechanical ventilation or non-invasive ventilation
Frequent use of rescue opioids >8x/day or rescue bronchodilators >8x/day over last 24 hours
Currently requiring high flow oxygen for oxygenation

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02932332). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.